Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC

This is a global Phase 2, multicenter, single-arm, open label study of taletrectinib in patients of NSCLC harboring with ROS1 fusion gene. About 214 patients will be enrolled and divided into 5 cohorts, depending on past history of ROS1 TKI treatment. Taletrectinib is administered once daily in 21-day cycles. Patients will continue with the treatment on taletrectinib until progression of disease as determined by the investigator. The tumor response evaluation will be conducted on a regular basis until progression of disease. Long-term survival follow-up will also be conducted.